Webinar: Update on CAR-T

CAR T-cell therapy (Chimeric Antigen Receptor) is a new type of cancer immunotherapy that uses genetically engineered T cells with synthetic antigen-specific receptors. This is a revolutionary new approach in cancer treatment.

Lymphocyte collection through leukapheresis is an essential step for CAR-T cell therapy. An optimal leukapheresis product is necessary for the success of manufacturing CAR-T cells.

Successful CAR-T cell therapies are so far associated with T cells engineered with viral vectors. Futur development focus on non-viral technologies (Alex Morell et al, Front. Immunol 2022).

The future begins now!

Speakers

Miquel Lozano

Miquel Lozano, MD, PhD is hematologist and Hemotherapy Section Head at the department of Hemotherapy and Hemostasis at the Clínic University Hospital of Barcelona, Spain. He is currently Vice-President Europe of the World Apheresis Association and past president of the European Society for Haemapheresis. He is a frequently invited and well known speaker in national and international meetings.

Julio Delgado

Julio Delgado, MD is the Head of the Oncoimmunotherapy Unit and consultant haematologist at Hospital Clínic, Barcelona (HCB) and associate professor at the University of Barcelona. He has been involved in the clinical development of ARI-0001 (varnimcabtagene autoleucel), the first 100% academic CART-cell product ever approved in a EU member state. He is a founding member of the Spanish Group for CLL and runs most CLL and CART-cell clinical trials at HCB.

Moderator

Gerda Leitner, MD, is specialist for transfusion medicine and general medicine. She was medical director of the University Clinic for Blood Group Serology and Transfusion Medicine (Medical University/Vienna, Austria) and retired at the end of 2021. She is currently President elect of the European Society for Haemapheresis.

View Webinar

To view the webinar please register here.